AAN 2025: PrimeC reduces miRNAs linked to ALS progression
Neurosense Therapeutics’ oral therapy PrimeC significantly reduces blood levels of miRNAs — molecules involved in regulating gene activity — associated…
Articles by Margarida Maia, PhD
Silence ALS treats 9 patients’ rare ALS caused by CHCHD10 mutations
Nine patients with an ultra-rare form of amyotrophic lateral sclerosis (ALS) caused by mutations in the CHCHD10 gene were…
Health Canada set to consider giving early approval to PrimeC for ALS
Health Canada has invited Neurosense Therapeutics to discuss the potential for giving conditional approval to PrimeC in treating…
QRL-101 reduces motor neuron excitability in healthy volunteers
An experimental oral small molecule being developed by Quralis for amyotrophic lateral sclerosis (ALS) reduced motor neuron excitability…
Cognixion seeks ALS patients for clinical trial of BCI headset
Cognixion is recruiting adults with amyotrophic lateral sclerosis (ALS) for a clinical trial testing ONE Axon-R, a wearable headset…
39 Canadians in ALS community presented with Coronation Medals
The ALS Society of Canada (ALS Canada) has named 39 Canadians to be presented the King Charles III Coronation…
Smartphone app may help in monitoring ALS beyond clinic visits
Using a smartphone app to self-assess ALS Functional Rating Scale-Revised (ALSFRS-R) scores, a standardized measure of amyotrophic lateral sclerosis…
MDA Shamrocks fundraising campaign underway across US
The Muscular Dystrophy Association (MDA) has rolled out its St. Patrick’s Day fundraising campaign, MDA Shamrocks —…
ALS patient’s story to be highlight of Atlanta Night of Hope Gala
This year’s Atlanta Night of Hope Gala will showcase how patient April Byars has been navigating life since her…
15 nonprofits join to form new ALS group, ALS United
Fifteen nonprofit organizations across the U.S. formed a new ALS group, ALS United, to better address the needs of…